JP2013530964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530964A5 JP2013530964A5 JP2013514787A JP2013514787A JP2013530964A5 JP 2013530964 A5 JP2013530964 A5 JP 2013530964A5 JP 2013514787 A JP2013514787 A JP 2013514787A JP 2013514787 A JP2013514787 A JP 2013514787A JP 2013530964 A5 JP2013530964 A5 JP 2013530964A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- src
- syk
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 230000000694 effects Effects 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 241000430519 Human rhinovirus sp. Species 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000036963 noncompetitive effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- UEVKQZYDMONRFV-UHFFFAOYSA-N 2-[4-[4-[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]naphthalen-1-yl]oxypyridin-2-yl]-2-methoxyacetamide Chemical compound COC(C(N)=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc(C)cc3)C(C)(C)C)c3ccccc23)ccn1 UEVKQZYDMONRFV-UHFFFAOYSA-N 0.000 claims 1
- MTEZLAATISORQK-UHFFFAOYSA-N 2-methoxyacetamide Chemical compound COCC(N)=O MTEZLAATISORQK-UHFFFAOYSA-N 0.000 claims 1
- -1 4- (4- (3- (3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl) ureido) naphthalen-1-yloxy) pyridin-2-yl Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000013000 chemical inhibitor Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims 1
- 229960000471 pleconaril Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1010196.2A GB201010196D0 (en) | 2010-06-17 | 2010-06-17 | Methods |
| GB1010196.2 | 2010-06-17 | ||
| PCT/GB2010/052066 WO2011070368A1 (en) | 2009-12-11 | 2010-12-10 | Antiviral use of urea compounds |
| GBPCT/GB2010/052066 | 2010-12-10 | ||
| PCT/GB2011/051139 WO2011158042A2 (en) | 2010-06-17 | 2011-06-17 | Methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530964A JP2013530964A (ja) | 2013-08-01 |
| JP2013530964A5 true JP2013530964A5 (enExample) | 2014-08-07 |
| JP6159251B2 JP6159251B2 (ja) | 2017-07-05 |
Family
ID=42471820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514787A Active JP6159251B2 (ja) | 2010-06-17 | 2011-06-17 | 方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130123260A1 (enExample) |
| EP (1) | EP2582433B1 (enExample) |
| JP (1) | JP6159251B2 (enExample) |
| CN (1) | CN103096978A (enExample) |
| AU (1) | AU2011266797B2 (enExample) |
| GB (1) | GB201010196D0 (enExample) |
| WO (1) | WO2011158042A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PE20142355A1 (es) | 2011-10-03 | 2015-01-10 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38 |
| TW201341367A (zh) * | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | ３，５－二胺基吡唑激酶抑制劑 |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) * | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| BR112015024671A2 (pt) * | 2013-04-02 | 2017-07-18 | Respivert Ltd | derivados de ureia úteis como inibidores de quinase |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| HUE049801T2 (hu) | 2014-12-23 | 2020-10-28 | Sma Therapeutics Inc | 3,5-diaminopirazol kináz inhibitorok |
| AU2017245888B2 (en) | 2016-04-06 | 2021-05-13 | Oxular Acquisitions Limited | Kinase inhibitors |
| EP3645010A4 (en) * | 2017-06-27 | 2021-03-24 | Ohio State Innovation Foundation | NUCLEOTIDE-BASED THERAPY FOR ASTHMA |
| CN114144410A (zh) | 2019-07-19 | 2022-03-04 | 阿纳格纳斯生物技术股份有限公司 | 多芳基脲衍生物及其在治疗肌肉疾病中的用途 |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2002939A3 (cs) * | 1999-09-17 | 2002-11-13 | Smithkline Beecham Corporation | Léčivo pro léčení rýmy nebo virové infekce dýchacích cest a pneumonie indukované chřipkou |
| EP1609789A1 (en) * | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| GB0500435D0 (en) * | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| US20070110760A1 (en) * | 2005-01-14 | 2007-05-17 | Monroe John G | Methods and compositions targeting viral and cellular ITAM motifs, and use of same in identifying compounds with therapeutic activity |
| JP2010518860A (ja) * | 2007-02-20 | 2010-06-03 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Ｌｙｎキナーゼの活性化剤の同定方法 |
| EP2313406B1 (de) * | 2008-08-05 | 2015-02-25 | Boehringer Ingelheim International GmbH | 4-dimethylaminophenyl-substituierte napththyridine und ihre verwendung als arzneimittel |
| KR20110070887A (ko) * | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | Ｐ38 엠에이피 키나제 억제제 |
| GB0818033D0 (en) * | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| JP5670912B2 (ja) * | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921731D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
-
2010
- 2010-06-17 GB GBGB1010196.2A patent/GB201010196D0/en not_active Ceased
-
2011
- 2011-06-17 AU AU2011266797A patent/AU2011266797B2/en active Active
- 2011-06-17 EP EP11729150.0A patent/EP2582433B1/en active Active
- 2011-06-17 JP JP2013514787A patent/JP6159251B2/ja active Active
- 2011-06-17 US US13/805,485 patent/US20130123260A1/en not_active Abandoned
- 2011-06-17 WO PCT/GB2011/051139 patent/WO2011158042A2/en not_active Ceased
- 2011-06-17 CN CN2011800298034A patent/CN103096978A/zh active Pending
-
2015
- 2015-10-27 US US14/924,541 patent/US20160045482A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513596A5 (enExample) | ||
| JP6569908B2 (ja) | 抗がん剤組成物 | |
| US11485732B2 (en) | Compounds and uses thereof | |
| US9708247B2 (en) | Modulators of the eIF2alpha pathway | |
| US12551482B2 (en) | Aurora kinase inhibitors | |
| KR20140098759A (ko) | 바이러스성 질환의 치료에 유용한 조성물 | |
| EA032480B1 (ru) | Способы повышения устойчивости скелетных мышц к утомлению | |
| CA3021675C (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| JP2017502967A5 (enExample) | ||
| CN107207510B (zh) | 联合疗法 | |
| WO2016198698A2 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| WO2009027069A3 (de) | Osmolyte zur behandlung von allergisch oder viral bedingten atemwegserkrankungen | |
| Ashton et al. | hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases | |
| KR20140036305A (ko) | 유기 화합물 | |
| AU2017281980A1 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| JP2010518860A5 (enExample) | ||
| US20200016147A1 (en) | Small-molecule ut-a-selective urea transport inhibitors | |
| JP2013505446A (ja) | Ｉａｐ阻害剤化合物のためのバイオマーカー | |
| RS61630B1 (sr) | Jedinjenja aminotiolestra ili njihove farmaceutski prihvatljive soli, za upotrebu u lečenju kancera | |
| Wu et al. | Effects of ibandronate sodium, a nitrogen-containing bisphosphonate, on intermediate-conductance calcium-activated potassium channels in osteoclast precursor cells (RAW 264.7) | |
| US11884649B2 (en) | IRE1α inhibitors and uses thereof | |
| JP2021521132A5 (enExample) | ||
| US20190256491A1 (en) | Methods For Treatment Of 16P11.2 Microdeletion Syndrome | |
| US20210220331A1 (en) | Inhibitors of ires-mediated protein synthesis |